RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clinuvel Pharmaceuticals Stock

Clinuvel Pharmaceuticals EBIT 2024

Clinuvel Pharmaceuticals EBIT

57.07 M AUD

Ticker

CUV.AX

ISIN

AU000000CUV3

WKN

A0JEGY

In 2024, Clinuvel Pharmaceuticals's EBIT was 57.07 M AUD, a 15.69% increase from the 49.33 M AUD EBIT recorded in the previous year.

The Clinuvel Pharmaceuticals EBIT history

YEAREBIT (undefined AUD)
2030e-
2029e86.89
2028e71.25
2027e68.86
2026e52.75
2025e46.28
202457.07
202349.33
202236.92
202129.66
202013.96
201917.26
201812.48
20177.06
2016-3.34
2015-10.48
2014-5.5
2013-6.88
2012-9.67
2011-11.41
2010-12.36
2009-13.55
2008-14.66
2007-9.06
2006-9.54
2005-11.03

Clinuvel Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Clinuvel Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Clinuvel Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Clinuvel Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Clinuvel Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Clinuvel Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Clinuvel Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Clinuvel Pharmaceuticals’s growth potential.

Clinuvel Pharmaceuticals Revenue, EBIT and net profit per share

DateClinuvel Pharmaceuticals RevenueClinuvel Pharmaceuticals EBITClinuvel Pharmaceuticals Net Income
2030e168.5 M undefined0 undefined70.36 M undefined
2029e161.13 M undefined86.89 M undefined67.87 M undefined
2028e131.44 M undefined71.25 M undefined55.89 M undefined
2027e143.28 M undefined68.86 M undefined53.4 M undefined
2026e106.53 M undefined52.75 M undefined40.27 M undefined
2025e97.8 M undefined46.28 M undefined35.77 M undefined
202495.5 M undefined57.07 M undefined35.64 M undefined
202382.23 M undefined49.33 M undefined30.6 M undefined
202266.17 M undefined36.92 M undefined20.88 M undefined
202148.32 M undefined29.66 M undefined24.73 M undefined
202033.13 M undefined13.96 M undefined15.05 M undefined
201931.61 M undefined17.26 M undefined18.13 M undefined
201825.75 M undefined12.48 M undefined13.22 M undefined
201717.03 M undefined7.06 M undefined7.18 M undefined
20167.03 M undefined-3.34 M undefined-3.12 M undefined
20153.67 M undefined-10.48 M undefined-10.41 M undefined
20142.99 M undefined-5.5 M undefined-5.53 M undefined
20132.9 M undefined-6.88 M undefined-6.8 M undefined
20121.29 M undefined-9.67 M undefined-9.77 M undefined
20112.28 M undefined-11.41 M undefined-11.41 M undefined
20101.85 M undefined-12.36 M undefined-11.52 M undefined
20092.91 M undefined-13.55 M undefined-15.37 M undefined
20084.3 M undefined-14.66 M undefined-14.66 M undefined
20072.55 M undefined-9.06 M undefined-9.18 M undefined
20061.2 M undefined-9.54 M undefined-10.77 M undefined
2005600,000 undefined-11.03 M undefined-11.03 M undefined

Clinuvel Pharmaceuticals stock margins

The Clinuvel Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clinuvel Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clinuvel Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Clinuvel Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Clinuvel Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Clinuvel Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Clinuvel Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Clinuvel Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Clinuvel Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Clinuvel Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Clinuvel Pharmaceuticals Margin History

Clinuvel Pharmaceuticals Gross marginClinuvel Pharmaceuticals Profit marginClinuvel Pharmaceuticals EBIT marginClinuvel Pharmaceuticals Profit margin
2030e101.16 %0 %41.76 %
2029e101.16 %53.93 %42.12 %
2028e101.16 %54.21 %42.52 %
2027e101.16 %48.06 %37.27 %
2026e101.16 %49.51 %37.8 %
2025e101.16 %47.32 %36.57 %
2024101.16 %59.76 %37.31 %
2023109.35 %59.99 %37.22 %
202297.95 %55.8 %31.55 %
2021103.93 %61.39 %51.18 %
202097.44 %42.14 %45.43 %
2019101.16 %54.58 %57.36 %
2018101.16 %48.46 %51.36 %
2017101.16 %41.48 %42.17 %
2016101.16 %-47.54 %-44.41 %
2015101.16 %-285.82 %-284.07 %
2014101.16 %-183.95 %-184.95 %
2013101.16 %-237.24 %-234.48 %
2012101.16 %-749.61 %-757.36 %
2011101.16 %-500.44 %-500.44 %
2010101.16 %-668.11 %-622.7 %
2009101.16 %-465.64 %-528.18 %
2008101.16 %-340.93 %-340.93 %
2007101.16 %-355.29 %-360 %
2006101.16 %-795 %-897.5 %
2005101.16 %-1,838.33 %-1,838.33 %

Clinuvel Pharmaceuticals Aktienanalyse

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that specializes in researching, developing, and marketing drugs targeting skin pigmentation. The company was founded in 1987 and is headquartered in Melbourne, Australia. It has become a leading expert in the field of light and pigment medicine since its establishment. Clinuvel's business model focuses on utilizing innovative technologies and scientific research to develop new products and therapies that benefit patients worldwide. The company specializes in developing safe and effective drugs based on research in therapeutic areas such as skin pigment disorders and skin cancer prevention. In recent years, the company has expanded its various divisions to meet market demand and extend innovations to other areas of medicine. Clinuvel's main divisions are Pharmaceuticals and Nutraceuticals. Clinuvel's pharmaceutical division specializes in developing new drugs and therapies for modulating skin pigmentation. The company is particularly known for its flagship product, SCENESSE, an implant that allows people with the rare condition erythropoietic protoporphyria (EPP) to live without pain in the sun. SCENESSE has received European and Australian approvals and is prescribed worldwide by a growing network of treatment centers. Clinuvel's nutraceutical division focuses on developing dietary supplements and advising patients who want to improve their skin from within. This includes products like Cuvita, a dietary supplement containing antioxidants and other nutrients that can contribute to the health of hair, skin, and nails. Clinuvel has expanded its business models to meet the needs of patients in different regions of the world. For example, the company has developed a comprehensive integration strategy in Europe to promote research, development, and marketing of innovative products and therapies. Overall, Clinuvel Pharmaceuticals is a company that focuses on developing innovative drugs and therapies in the field of light and pigment medicine. It is known for its advanced research, successful development of SCENESSE, and commitment to patients worldwide. It will be interesting to see how the divisions develop in the future, but innovative drugs and therapies are definitely an important part of Clinuvel's future. Clinuvel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Clinuvel Pharmaceuticals's EBIT

Clinuvel Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Clinuvel Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Clinuvel Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Clinuvel Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Clinuvel Pharmaceuticals stock

How much did Clinuvel Pharmaceuticals achieve in EBIT for the current year?

In the current year, Clinuvel Pharmaceuticals has achieved an EBIT of 57.07 M AUD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Clinuvel Pharmaceuticals.

How has the EBIT of Clinuvel Pharmaceuticals developed in recent years?

The EBIT of Clinuvel Pharmaceuticals has increased by 15.694% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Clinuvel Pharmaceuticals?

The EBIT of Clinuvel Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Clinuvel Pharmaceuticals pay?

Over the past 12 months, Clinuvel Pharmaceuticals paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 0.5 %. For the coming 12 months, Clinuvel Pharmaceuticals is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Clinuvel Pharmaceuticals?

The current dividend yield of Clinuvel Pharmaceuticals is 0.5 %.

When does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals paid dividends every year for the past 13 years.

What is the dividend of Clinuvel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 0.57 %.

In which sector is Clinuvel Pharmaceuticals located?

Clinuvel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinuvel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinuvel Pharmaceuticals from 9/20/2024 amounting to 0.071 AUD, you needed to have the stock in your portfolio before the ex-date on 9/5/2024.

When did Clinuvel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Clinuvel Pharmaceuticals in the year 2023?

In the year 2023, Clinuvel Pharmaceuticals distributed 0.071 AUD as dividends.

In which currency does Clinuvel Pharmaceuticals pay out the dividend?

The dividends of Clinuvel Pharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Clinuvel Pharmaceuticals

Our stock analysis for Clinuvel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clinuvel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.